Figure 2.
Proposed antitumor mechanism of LL-37 in gastric cancer. LL-37 inhibits proteasomal activity via an unknown mechanism, which leads to upregulation of BMP4 and subsequent activation of BMP signaling. LL-37 also downregulates cyclin E2. These changes result in cell cycle arrest at the late G1-phase.